Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Protelos

- PMLiVE

EMA develops framework for academia collaborations

Looks to develop the way it works with the academic community

Shire Basingstoke

Shire finally bags EU approval for rare disease drug Natpar

Becomes first licenced treatment for hypoparathyroidism in Europe

EU flag

CHMP backs two rare disease therapies at April meeting

Biogen's Spinraza and BioMarin's Brineura near EU approval

EMA establishes big data taskforce

Will explore how research and medicines development can be supported

- PMLiVE

Pfizer launches new antibiotic Zavicefta in UK and Germany

Biopharmaceutical company Pfizer releases MDR antibiotic

- PMLiVE

Servier cleared to start US trials CAR-T therapy

FDA rules studies of its Pfizer-partnered drug can be resumed

- PMLiVE

Mundipharma to launch first MabThera biosimilar in EU

EMA approves Truxima in all indications licensed to Roche’s cancer drug

Roche Basel Switzerland

Roche’s lung cancer drug Alecensa wins EU approval

Monotherapy conditionally approved as second-line NSCLC treatment

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

- PMLiVE

Denmark pitches for EMA, with help from ex Novo Nordisk CEO

Lars Rebien Sørensen to serve as special envoy to promote Danish candidacy

- PMLiVE

Cellectis gets FDA nod for ‘off-the-shelf’ CAR-T trial

Investigational New Drug gets go-ahead for trials in patients with two haematological cancers

- PMLiVE

Brexit – a tough pill to swallow

What will be expected of the UK when the post-Brexit environment takes shape?

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links